PYC 0.00% 6.4¢ pyc therapeutics limited

Ann: Retina Target Engagement Confirmed in Large Eye, page-84

  1. 4,921 Posts.
    lightbulb Created with Sketch. 8840
    And yet another blow for an Ionis CNS antisense drug candidate….

    Following the announcement last October of Phase 3 failure of tofersen in adults with ALS associated with a SOD1 mutation, Biogen and Ionis have suffered another disappointment in the ALS pipeline after BIIB078 (IONIS-C9Rx) failed to demonstrate clinical benefit in a 106 patient Phase 1 trial. BIIB078 is an investigational antisense therapy for the treatment of C9orf72-associated ALS.

    No consistent difference was seen between the 60mg cohort and placebo and the 90mg cohort showed a greater decline on secondary endpoints than placebo.

    https://www.prnewswire.com/news-rel...-amyotrophic-lateral-sclerosis-301511359.html

    https://www.fiercebiotech.com/biote...t-quits-als-med-after-it-flunks-phase-1-trial

    https://pharmaphorum.com/news/new-b...ogen-and-ionis-candidate-fails-phase-1-trial/
 
watchlist Created with Sketch. Add PYC (ASX) to my watchlist
(20min delay)
Last
6.4¢
Change
0.000(0.00%)
Mkt cap ! $203.5M
Open High Low Value Volume
6.4¢ 6.4¢ 6.4¢ $4.633K 72.38K

Buyers (Bids)

No. Vol. Price($)
1 10417 6.2¢
 

Sellers (Offers)

Price($) Vol. No.
6.4¢ 137432 1
View Market Depth
Last trade - 14.26pm 17/08/2022 (20 minute delay) ?
PYC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.